WO2004073722A1 - スーパーオキサイドアニオン分解剤 - Google Patents
スーパーオキサイドアニオン分解剤 Download PDFInfo
- Publication number
- WO2004073722A1 WO2004073722A1 PCT/JP2004/001817 JP2004001817W WO2004073722A1 WO 2004073722 A1 WO2004073722 A1 WO 2004073722A1 JP 2004001817 W JP2004001817 W JP 2004001817W WO 2004073722 A1 WO2004073722 A1 WO 2004073722A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- decomposing agent
- platinum
- transition metal
- agent
- superoxide anion
- Prior art date
Links
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 title claims abstract description 22
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 59
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 17
- 229910052723 transition metal Inorganic materials 0.000 claims abstract description 17
- 150000003624 transition metals Chemical class 0.000 claims abstract description 17
- 229910000510 noble metal Inorganic materials 0.000 claims description 20
- 239000000084 colloidal system Substances 0.000 claims description 8
- 229910001260 Pt alloy Inorganic materials 0.000 claims description 2
- RLLPVAHGXHCWKJ-IEBWSBKVSA-N (3-phenoxyphenyl)methyl (1s,3s)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(Cl)Cl)[C@@H]1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-IEBWSBKVSA-N 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 abstract description 22
- -1 platinum Chemical class 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000010419 fine particle Substances 0.000 description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 17
- 239000001301 oxygen Substances 0.000 description 17
- 229910052760 oxygen Inorganic materials 0.000 description 17
- 238000000034 method Methods 0.000 description 14
- 229910052751 metal Inorganic materials 0.000 description 11
- 239000002184 metal Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 210000003470 mitochondria Anatomy 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 241000208125 Nicotiana Species 0.000 description 5
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 5
- 108010093894 Xanthine oxidase Proteins 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 229910045601 alloy Inorganic materials 0.000 description 4
- 239000000956 alloy Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 229910001111 Fine metal Inorganic materials 0.000 description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 3
- 102100033220 Xanthine oxidase Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 229910052703 rhodium Inorganic materials 0.000 description 3
- 239000010948 rhodium Substances 0.000 description 3
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 239000000779 smoke Substances 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- BPBUJYBQUBMWDT-VQHVLOKHSA-N (E)-hydroxyimino-[methyl-[3-(methylamino)propyl]amino]-oxidoazanium Chemical compound CNCCCN(C)[N+](\[O-])=N/O BPBUJYBQUBMWDT-VQHVLOKHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229910052741 iridium Inorganic materials 0.000 description 2
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052762 osmium Inorganic materials 0.000 description 2
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- BNXZHVUCNYMNOS-UHFFFAOYSA-N 1-butylpyrrolidin-2-one Chemical compound CCCCN1CCCC1=O BNXZHVUCNYMNOS-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- VCUVETGKTILCLC-UHFFFAOYSA-N 5,5-dimethyl-1-pyrroline N-oxide Chemical compound CC1(C)CCC=[N+]1[O-] VCUVETGKTILCLC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000009841 combustion method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 238000001362 electron spin resonance spectrum Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229930002839 ionone Natural products 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013319 spin trapping Methods 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a decomposer for a superoxide anion which is a kind of active oxygen.
- the superoxide anion decomposer of the present invention can be used as reduced water or pharmaceuticals.
- the present invention also relates to a nitric oxide decomposing agent. Background art
- microsomes such as in white blood cells, ⁇ (scan one Paokisaidoa two ON), H 2 0 2 (hydrogen peroxide), HO ⁇ (hydroxyl radicals), and the excitation species E 0 2 ( Many reactive oxygen species (radicals) that exhibit high reactivity, such as —barnet oxygen, are generated, and are said to be involved in biological control, including ecological defense and biochemical reactions.
- Nitric oxide (NO) is a short-lived unstable radical species, and it has been shown that this substance also has an important function in vivo as a kind of active oxygen (Hyundai Kagaku, 1994). April issue).
- the amount of these reactive oxygen species produced is about 1% of the equivalent of the main oxidation-reduction reaction, and is metabolized sequentially by decomposing enzymes.
- antioxidant enzymes cannot remove all active oxygen, and some of the active oxygen oxidizes proteins, lipids, nucleic acids and the like. Although these oxidized substances are partially repaired by another body defense mechanism, they are gradually irreversible. Oxidatively damaged substances are formed. As a result, it is said to lead to illness and aging.
- antioxidant enzymes such as superoxide desmutes decreases with age. If the metabolism of these oxides is too late to accumulate due to a decrease in metabolic capacity of reactive oxygen species due to aging or excessive production of reactive oxygen species due to disease, cell components such as lipids are oxidized non-specifically, and It can lead to cell death. This contributes to many diseases such as aging and Alzheimer's.
- the present inventors have developed a method for efficiently eliminating o 2 _ (superoxide aion) and nitric oxide among active oxygen generated in a living body, and eliminating an excessive state of these active oxygens in a living body.
- the present inventors have focused on transition metal fine powder, particularly platinum fine powder, which is a noble metal, and have found that these fine powders can enter cells and can also enter mitochondria. Has the ability to eliminate superoxide anion and nitric oxide inside mitochondria.
- the present invention has been completed based on the above findings.
- the present invention provides a superoxide anion decomposing agent containing a fine powder of a transition metal.
- the above-described superoxide decomposer wherein the transition metal is a fine powder of a noble metal. This decomposer can degrade superoxide anion in a living body.
- the present invention provides a nitric oxide decomposing agent containing a fine powder of a transition metal.
- a nitric oxide decomposing agent containing a fine powder of a transition metal.
- the transition metal is a fine powder of a noble metal.
- the decomposer wherein the fine powder is a fine platinum powder or a fine platinum alloy powder; an aqueous decomposer containing a transition metal colloid; 1 mM or less in 100 ml; An aqueous decomposer comprising a transition metal colloid in a proportion of
- a method for eliminating superoxide or nitric oxide in a living body of a mammal, including a human including a step of administering a fine powder of a transition metal to the living body.
- a method for eliminating superoxide or nitric oxide in a living body of a mammal, including a human including a step of administering a fine powder of a transition metal to the living body.
- water containing a transition metal colloid can be administered.
- FIG. 1 is a diagram showing the action of the nitric oxide decomposing agent of the present invention.
- the type of transition metal in the decomposition agent of the present invention is not particularly limited, and specific metals include metals such as gold, nickel, platinum, rhodium, palladium, iridium, ruthenium, and osmium, and alloys thereof. .
- the transition metal is preferably a noble metal.
- the type of the noble metal is not particularly limited, and any one of gold, ruthenium, rhodium, palladium, osmium, iridium, and platinum may be used.
- Preferred noble metals are ruthenium, rhodium, palladium, and platinum.
- a particularly preferred noble metal is platinum.
- the noble metal particles may contain two or more noble metals.
- fine particles of an alloy containing at least one kind of noble metal or a mixture containing fine particles of one or more kinds of noble metals and fine particles of one or more kinds of metals other than noble metals can also be used.
- an alloy made of gold and platinum may be used.
- platinum or an alloy containing platinum is preferable, and platinum is particularly preferable.
- the fine particles of the noble metal fine particles having a large specific surface area and capable of forming a colloidal state having excellent surface reactivity are preferable.
- the particle size of the fine particles is not particularly limited, fine particles having an average particle size of 50 sq. Or less can be used, preferably the average particle size is 20 nm or less, more preferably the average particle size is 10 nm or less, Particularly preferably, fine particles having an average particle size of about 1 to 6 nm can be used. In particular, the average particle diameter is preferably about 1 to 6 nm for intrusion into mitochondria. It is also possible to use finer fine particles, which is preferable for increasing the incorporation into the living body.
- a decomposer containing these fine particles in a stable suspension state in an aqueous medium is also preferable.
- the aqueous medium in addition to water, an organic solvent having low toxicity to the living body and being mixed with water at an arbitrary ratio, for example, ethanol, ethylene glycol, and the like can be used.
- water can be used as the aqueous medium.
- Various methods for producing noble metal fine particles are known (for example, JP-B-57-43125, JP-B-59-120249, JP-A-9-225317, JP-A-10-176207, and JP-A-2001-176207.
- fine particles prepared by any method may be used, but from the viewpoint of easiness of production and quality, fine particles prepared by a metal salt reduction reaction method are preferably used.
- an aqueous or organic solvent solution of a water-soluble or organic solvent-soluble noble metal salt or noble metal complex is prepared, and after adding a water-soluble polymer to this solution, the pH of the solution is adjusted to 9 to 10%. It is adjusted to 11 and reduced by heating and refluxing under an inert atmosphere to obtain metal fine particles.
- the kind of the water-soluble or organic solvent-soluble salt of the noble metal is not particularly limited, and for example, acetate, chloride, sulfate, nitrate, sulfonate, phosphate, or the like can be used. May be used.
- the type of the water-soluble polymer used in the metal salt reduction reaction is not particularly limited, but for example, use is made of polybierpyrrolidone, polybutyl alcohol, polyacrylic acid, cyclodextrin, aminopectin, or methylcellulose. These may be used in combination of two or more.
- polybutylpyrrolidone can be used, and more preferably, poly (1-butyl-2-pyrrolidone) can be used.
- various surfactants such as anionic, nonionic or lipophilic surfactants can be used instead of or together with the water-soluble polymer.
- the method of preparing the noble metal fine particles is not limited to the method described above.
- the fine metal powder prepared by the above method is usually rolled with the solvent used as a medium. Since it is obtained in the oxidized state, it can be used as it is as a superoxide deionizing agent or a nitric oxide decomposing agent of the present invention.
- the decomposing agent of the present invention can be prepared as a fine metal powder by removing the organic solvent by heating. The fine metal powder obtained by heating and drying does not lose its properties as a superoxide ionone decomposer or a nitric oxide decomposer.
- the decomposing agent of the present invention can be prepared in the form of reduced water. Reduced water is water that has the action of reducing oxidized substances in living organisms.
- reduced water that decomposes superoxide aion and / or nitric oxide can be prepared according to the amount of the added decomposing agent.
- a sufficient reducing effect that is, a decomposition effect of superoxide anion and / or nitric oxide, can be obtained even with reduced water to which about 33 mM of a decomposing agent is added.
- the reduced water of the present invention preferably contains the above-mentioned decomposing agent at a ratio of 1 mM or less.
- the decomposing agent of the present invention contains a metal fine powder having a particle size on the order of nanometers.
- the decomposing agent of the present invention is expected to be effective for the prevention or treatment of the above-mentioned diseases attributed to active oxygen, particularly amyotrophic lateral sclerosis (FALS).
- FALS amyotrophic lateral sclerosis
- the decomposing agent of the present invention which is provided in the form of reduced water, can be used as drinking water or sports drink as a health food, and can be used as a medicine or a cosmetic itself, and can also be used for manufacturing a health food. It can also be used for the production of pharmaceuticals or cosmetics.
- nitric oxide decomposing agent of the present invention with, for example, a filter for tobacco or the like, it is possible to efficiently decompose nitric oxide contained in tobacco smoke.
- fine particles of the decomposing agent of the present invention can be blended in a tobacco filter in a solid state together with activated carbon or the like or in place of activated carbon.
- the decomposing agent of the present invention in an aqueous colloid state is filled in a water pipe, and tobacco smoke is guided into the water pipe, whereby nitric oxide contained in tobacco smoke can be efficiently removed.
- Example 1 the present invention will be described more specifically with reference to Examples, but the scope of the present invention is not limited to the following Examples.
- Example 1 the present invention will be described more specifically with reference to Examples, but the scope of the present invention is not limited to the following Examples.
- the obtained decomposing agent was dissolved in a 0.1 M sodium phosphate buffer having a concentration adjusted to 7.8 in advance, and the resulting solution was dissolved in 0.66 mM, 0.495 mM, 0.330 mM, 0.1 mM. Dispersions containing colloidal decomposers at concentrations of 65 mM, 0.083 mM, and 0.033 mM were obtained. Observation under a microscope revealed that the particle size of the platinum particles was 6 nanometers or less.
- O 2 superoxide anion
- N0 2 / N0 3 Assay Kit- C II as an analysis kit Dojin Chemical Laboratories, Ltd. have use were studied scavenging ability of NO with platinum colloid.
- This kit is for measuring the NO 2 which NO has occurred construed hydrolysis min.
- a microplate reader Model 550 manufactured by BI0RAD
- the detection wavelength was set to 570 nm, and the measurement was performed three times for each sample.
- a 96-well microplate was used as the microplate.
- NOC 7 (Dojindo Laboratories, Inc.) was used as the NO donor. Analysis is basic This was done according to the manual that came with the kit, with some modifications.
- the superoxide anion decomposing agent and the nitric oxide decomposing agent of the present invention can decompose excessive superoxide anion and Z or nitric oxide in a living body by being administered to a living body. .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04712229A EP1598071A4 (en) | 2003-02-20 | 2004-02-18 | DECOMPOSING AGENT OF SUPEROXIDE ANION |
JP2005502741A JP4058072B2 (ja) | 2003-02-20 | 2004-02-18 | スーパーオキサイドアニオン分解剤 |
US10/545,750 US7838043B2 (en) | 2003-02-20 | 2004-02-18 | Superoxide anion decomposing agent |
AU2004212823A AU2004212823A1 (en) | 2003-02-20 | 2004-02-18 | Superoxide anion scavenger |
CA002518311A CA2518311A1 (en) | 2003-02-20 | 2004-02-18 | Superoxide anion scavenger |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-042452 | 2003-02-20 | ||
JP2003042452 | 2003-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004073722A1 true WO2004073722A1 (ja) | 2004-09-02 |
Family
ID=32905350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/001817 WO2004073722A1 (ja) | 2003-02-20 | 2004-02-18 | スーパーオキサイドアニオン分解剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US7838043B2 (ja) |
EP (1) | EP1598071A4 (ja) |
JP (1) | JP4058072B2 (ja) |
KR (1) | KR20060007365A (ja) |
CN (2) | CN100446776C (ja) |
AU (1) | AU2004212823A1 (ja) |
CA (1) | CA2518311A1 (ja) |
RU (1) | RU2353372C2 (ja) |
TW (1) | TW200418733A (ja) |
WO (1) | WO2004073722A1 (ja) |
ZA (2) | ZA200507289B (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1842524A1 (en) * | 2004-12-13 | 2007-10-10 | APT Co., Ltd. | Cleaning liquid for oral cavity |
JP2009155281A (ja) * | 2007-12-27 | 2009-07-16 | Univ Of Tokyo | 細胞透過性白金微粒子 |
US7588747B2 (en) | 2003-08-22 | 2009-09-15 | Kose Corporation | Singlet oxygen quencher and composition using the same |
JP2013212498A (ja) * | 2012-03-07 | 2013-10-17 | Tatehiko Ogawa | 還元パウダー及びその製造方法 |
JP7039083B1 (ja) * | 2021-07-29 | 2022-03-22 | 株式会社東洋厚生製薬所 | Ampk活性化剤 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060099232A1 (en) * | 2004-11-08 | 2006-05-11 | Fuji Photo Film Co., Ltd. | Active oxygen eliminator and production method thereof |
TWI298646B (en) * | 2005-12-28 | 2008-07-11 | Ind Tech Res Inst | Process for preparing platinum based electrode catalyst for use in direct methanol fuel cell |
CN104450864A (zh) * | 2014-12-18 | 2015-03-25 | 三诺生物传感股份有限公司 | 一种组合物及其应用 |
SG11201706285VA (en) * | 2015-02-04 | 2017-09-28 | Eupharma Pty Ltd | Ruthenium and indium binding to gastrins |
WO2021033590A1 (ja) | 2019-08-20 | 2021-02-25 | 有正 宮本 | 屁及び/又は大便の悪臭の低減剤 |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03243638A (ja) * | 1990-02-20 | 1991-10-30 | Toda Kogyo Corp | 着色フォーム |
EP0832846A2 (de) * | 1996-09-30 | 1998-04-01 | Basf Aktiengesellschaft | Polymer-Wasserstoffperoxid-komplexe |
WO1998014199A1 (de) * | 1996-09-30 | 1998-04-09 | Basf Aktiengesellschaft | Topische mittel zur prophylaxe oder behandlung bakterieller hautinfektionen |
JPH1160493A (ja) * | 1997-08-18 | 1999-03-02 | Eiichi Tsukiji | 活性酸素を起因とする疾患の治療および予防薬又はその原料 |
WO1999042112A1 (fr) * | 1998-02-23 | 1999-08-26 | Ohtuka Chemical Industrial Co., Ltd. | Procede de preparation d'une preparation solide au moyen d'un colloide de platine et de palladium utilise en tant que matiere brute de depart et utilisation de cette preparation |
JPH11346715A (ja) * | 1998-06-09 | 1999-12-21 | Otsuka Yakuhin Kogyo Kk | 白金族コロイド溶液を配合した食品の製造方法 |
JP2000232865A (ja) * | 1999-02-16 | 2000-08-29 | Otsuka Yakuhin Kogyo Kk | 生命現象活性化物の製造方法 |
JP2001010954A (ja) * | 1999-06-29 | 2001-01-16 | Otsuka Sangyo Kk | 酸化的ストレスに対する保護剤 |
JP2001114671A (ja) * | 1999-10-15 | 2001-04-24 | Otsuka Yakuhin Kogyo Kk | 貼付剤 |
WO2001076572A2 (de) * | 2000-04-12 | 2001-10-18 | bitop Aktiengesellschaft für biotechnische Optimierung | Verwendung von kompatiblen soluten als substanzen mit radikalfangenden eigenschaften |
JP2002060805A (ja) * | 2000-08-24 | 2002-02-28 | Chemiprokasei Kaisha Ltd | 多元複合系金属粒子コロイド分散液の製造方法 |
JP2002212102A (ja) * | 2001-01-23 | 2002-07-31 | Ainobekkusu Kk | 電気化学的生理活性微粒子 |
JP2002241288A (ja) * | 2001-02-20 | 2002-08-28 | Shiro Yamashita | 白金微粉末を配合した皮膚疾患緩和剤の製造方法 |
JP2003012523A (ja) * | 2001-07-05 | 2003-01-15 | Otsuka Yakuhin Kogyo Kk | パーキンソン病患者のqol改善剤 |
JP2003301288A (ja) * | 2002-04-10 | 2003-10-24 | Nippon Torimu:Kk | コロイド含有電解還元水およびその製造方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53109878A (en) | 1977-03-09 | 1978-09-26 | Hidefumi Hirai | Manufacture of rare metal colloid |
JPS59120249A (ja) | 1982-12-27 | 1984-07-11 | Agency Of Ind Science & Technol | 貴金属触媒の製造方法 |
GB9309387D0 (en) | 1993-05-06 | 1993-06-16 | Wellcome Found | Nitric oxide scavengers |
JPH09225317A (ja) | 1996-02-26 | 1997-09-02 | Kemipuro Kasei Kk | ニッケル/貴金属二元金属クラスター、それよりなる触媒およびその製法 |
JPH1068008A (ja) | 1996-08-27 | 1998-03-10 | I Betsukusu:Kk | 高活性金属微粒子の製造方法 |
JPH10176207A (ja) | 1996-12-18 | 1998-06-30 | I Betsukusu:Kk | 高活性貴金属クラスター |
JP4505084B2 (ja) | 1999-09-13 | 2010-07-14 | アイノベックス株式会社 | 金属コロイドの製造方法およびその方法によって製造された金属コロイド |
JP4926312B2 (ja) | 1999-10-27 | 2012-05-09 | アイノベックス株式会社 | 白金コロイド含有化粧品 |
JP3432778B2 (ja) | 1999-11-19 | 2003-08-04 | 森澤 紳勝 | 活性酸素消去剤の濃縮液、その製造方法および活性酸素消去剤パウダー |
BR0210726A (pt) | 2001-06-29 | 2004-07-20 | Miz Co Ltd | Método de anti-oxidação e água que funciona como anti-oxidante |
EP1283274B1 (de) * | 2001-08-04 | 2007-10-31 | Umicore AG & Co. KG | Chlorarme Platin- und Platinlegierungspulver mit erhöhter spezifischer Oberfläche und Verfahren zu ihrer Herstellung unter Verwendung einer Nitratsalzschmelze |
EP1550637A1 (en) | 2002-04-26 | 2005-07-06 | MIZ Co., Ltd. | Method of inhibiting oxidation, water capable of inhibiting oxidation and use thereof |
WO2004037019A1 (ja) * | 2002-10-28 | 2004-05-06 | Takaoka Shoji Inc. | 活性酸素消去能を有する金属組成物 |
KR20070030158A (ko) * | 2003-08-22 | 2007-03-15 | 코세 코퍼레이션 | 일중항산소 소거제 및 그것을 사용한 조성물 |
-
2004
- 2004-02-18 US US10/545,750 patent/US7838043B2/en not_active Expired - Fee Related
- 2004-02-18 WO PCT/JP2004/001817 patent/WO2004073722A1/ja active Application Filing
- 2004-02-18 EP EP04712229A patent/EP1598071A4/en not_active Withdrawn
- 2004-02-18 JP JP2005502741A patent/JP4058072B2/ja not_active Expired - Lifetime
- 2004-02-18 AU AU2004212823A patent/AU2004212823A1/en not_active Abandoned
- 2004-02-18 ZA ZA200507289A patent/ZA200507289B/en unknown
- 2004-02-18 ZA ZA200507288A patent/ZA200507288B/xx unknown
- 2004-02-18 KR KR1020057015423A patent/KR20060007365A/ko not_active Application Discontinuation
- 2004-02-18 CN CNB2004800045365A patent/CN100446776C/zh not_active Expired - Fee Related
- 2004-02-18 CA CA002518311A patent/CA2518311A1/en not_active Abandoned
- 2004-02-18 RU RU2005129269/15A patent/RU2353372C2/ru not_active IP Right Cessation
- 2004-02-18 CN CNA200480004537XA patent/CN1750838A/zh active Pending
- 2004-02-20 TW TW093104296A patent/TW200418733A/zh not_active IP Right Cessation
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03243638A (ja) * | 1990-02-20 | 1991-10-30 | Toda Kogyo Corp | 着色フォーム |
EP0832846A2 (de) * | 1996-09-30 | 1998-04-01 | Basf Aktiengesellschaft | Polymer-Wasserstoffperoxid-komplexe |
WO1998014199A1 (de) * | 1996-09-30 | 1998-04-09 | Basf Aktiengesellschaft | Topische mittel zur prophylaxe oder behandlung bakterieller hautinfektionen |
JPH1160493A (ja) * | 1997-08-18 | 1999-03-02 | Eiichi Tsukiji | 活性酸素を起因とする疾患の治療および予防薬又はその原料 |
WO1999042112A1 (fr) * | 1998-02-23 | 1999-08-26 | Ohtuka Chemical Industrial Co., Ltd. | Procede de preparation d'une preparation solide au moyen d'un colloide de platine et de palladium utilise en tant que matiere brute de depart et utilisation de cette preparation |
JPH11346715A (ja) * | 1998-06-09 | 1999-12-21 | Otsuka Yakuhin Kogyo Kk | 白金族コロイド溶液を配合した食品の製造方法 |
JP2000232865A (ja) * | 1999-02-16 | 2000-08-29 | Otsuka Yakuhin Kogyo Kk | 生命現象活性化物の製造方法 |
JP2001010954A (ja) * | 1999-06-29 | 2001-01-16 | Otsuka Sangyo Kk | 酸化的ストレスに対する保護剤 |
JP2001114671A (ja) * | 1999-10-15 | 2001-04-24 | Otsuka Yakuhin Kogyo Kk | 貼付剤 |
WO2001076572A2 (de) * | 2000-04-12 | 2001-10-18 | bitop Aktiengesellschaft für biotechnische Optimierung | Verwendung von kompatiblen soluten als substanzen mit radikalfangenden eigenschaften |
JP2002060805A (ja) * | 2000-08-24 | 2002-02-28 | Chemiprokasei Kaisha Ltd | 多元複合系金属粒子コロイド分散液の製造方法 |
JP2002212102A (ja) * | 2001-01-23 | 2002-07-31 | Ainobekkusu Kk | 電気化学的生理活性微粒子 |
JP2002241288A (ja) * | 2001-02-20 | 2002-08-28 | Shiro Yamashita | 白金微粉末を配合した皮膚疾患緩和剤の製造方法 |
JP2003012523A (ja) * | 2001-07-05 | 2003-01-15 | Otsuka Yakuhin Kogyo Kk | パーキンソン病患者のqol改善剤 |
JP2003301288A (ja) * | 2002-04-10 | 2003-10-24 | Nippon Torimu:Kk | コロイド含有電解還元水およびその製造方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1598071A4 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7588747B2 (en) | 2003-08-22 | 2009-09-15 | Kose Corporation | Singlet oxygen quencher and composition using the same |
EP1842524A1 (en) * | 2004-12-13 | 2007-10-10 | APT Co., Ltd. | Cleaning liquid for oral cavity |
JPWO2006064788A1 (ja) * | 2004-12-13 | 2008-06-12 | アプト株式会社 | 口腔内洗浄液 |
EP1842524A4 (en) * | 2004-12-13 | 2009-03-04 | Apt Co Ltd | CLEANING LIQUID FOR ORAL CAVITY |
JP2009155281A (ja) * | 2007-12-27 | 2009-07-16 | Univ Of Tokyo | 細胞透過性白金微粒子 |
JP2013212498A (ja) * | 2012-03-07 | 2013-10-17 | Tatehiko Ogawa | 還元パウダー及びその製造方法 |
JP7039083B1 (ja) * | 2021-07-29 | 2022-03-22 | 株式会社東洋厚生製薬所 | Ampk活性化剤 |
Also Published As
Publication number | Publication date |
---|---|
RU2353372C2 (ru) | 2009-04-27 |
JPWO2004073722A1 (ja) | 2006-06-01 |
TW200418733A (en) | 2004-10-01 |
CN1750837A (zh) | 2006-03-22 |
ZA200507288B (en) | 2007-03-28 |
TWI316051B (ja) | 2009-10-21 |
CA2518311A1 (en) | 2004-09-02 |
AU2004212823A1 (en) | 2004-09-02 |
US7838043B2 (en) | 2010-11-23 |
CN1750838A (zh) | 2006-03-22 |
US20060204593A1 (en) | 2006-09-14 |
ZA200507289B (en) | 2006-12-27 |
EP1598071A1 (en) | 2005-11-23 |
CN100446776C (zh) | 2008-12-31 |
KR20060007365A (ko) | 2006-01-24 |
EP1598071A4 (en) | 2006-04-26 |
RU2005129269A (ru) | 2006-03-10 |
JP4058072B2 (ja) | 2008-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Komkova et al. | Catalytically synthesized prussian blue nanoparticles defeating natural enzyme peroxidase | |
Liu et al. | Hydrogen peroxide displacing DNA from nanoceria: mechanism and detection of glucose in serum | |
KR100726057B1 (ko) | 항산화방법 및 항산화 기능수 | |
Yang et al. | Catalytic and peroxidase-like activity of carbon based-AuPd bimetallic nanocomposite produced using carbon dots as the reductant | |
Filon et al. | Human skin penetration of cobalt nanoparticles through intact and damaged skin | |
Gharib et al. | Protein-protected porous bimetallic AgPt nanoparticles with pH-switchable peroxidase/catalase-mimicking activity | |
Yakimovich et al. | Antioxidant properties of gold nanoparticles studied by ESR spectroscopy | |
Shang et al. | Enzyme mimic nanomaterials and their biomedical applications | |
Ma et al. | Copper (II) ions enhance the peroxidase-like activity and stability of keratin-capped gold nanoclusters for the colorimetric detection of glucose | |
WO2004073722A1 (ja) | スーパーオキサイドアニオン分解剤 | |
Jangi | Effect of daylight and air oxygen on nanozymatic activity of unmodified silver nanoparticles: Shelf-stability | |
CN113201334B (zh) | 一种铁氮掺杂石墨烯量子点及其制备方法和应用 | |
Tran et al. | Functionalized bimetallic IrPt alloy nanoparticles: Multi-enzyme mimics for colorimetric and fluorometric detection of hydrogen peroxide and glucose | |
CN107427586A (zh) | 具有过氧化氢酶样活性的edds螯合纳米铈氧化物 | |
Pandey et al. | Tetrahydrofuran and hydrogen peroxide mediated conversion of potassium hexacyanoferrate into Prussian blue nanoparticles: application to hydrogen peroxide sensing | |
Yan et al. | An enzymatic reaction mediated glucose sensor activated by MnO 2 nanosheets acting as an oxidant and catalyst | |
Aghayan et al. | Micellar catalysis of an iron (III)-MOF: enhanced biosensing characteristics | |
Shim et al. | Tunable porosity in bimetallic core-shell structured palladium-platinum nanoparticles for electrocatalysts | |
Wojtaszek et al. | Synthesis and catalytic studies of Nanoalloy particles based on bismuth, silver, and rhenium | |
Nanda et al. | Recent advances in synergistic effect of nanoparticles and its biomedical application | |
Liu et al. | Carbon dot enhanced peroxidase-like activity of platinum nanozymes | |
KR100842070B1 (ko) | 나노 플래티늄 진세노사이드 입자 및 그의 제조 방법 | |
JP2007176944A (ja) | 一酸化窒素分解剤 | |
EP3321014A1 (en) | Method for producing platinum colloid, and platinum colloid produced using such method | |
Alayli Gungor et al. | Green Synthesis of Nanoceria (CeO2) and Evaluation of Enzyme like Characteristics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005502741 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048045365 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057015423 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2518311 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004712229 Country of ref document: EP Ref document number: 2005/07288 Country of ref document: ZA Ref document number: 200507288 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004212823 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005129269 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2004212823 Country of ref document: AU Date of ref document: 20040218 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004212823 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004712229 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057015423 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10545750 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10545750 Country of ref document: US |